AoFrio strengthens its Commercial Team to support growth
www.aofrio.com
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd
A: 78 Apollo Drive, Rosedale Auckland 0632, New Zealand
PO Box: 302-533 North Harbour, Auckland 0751, New
Zealand
17 January 2024
AoFrio strengthens its Commercial Team to support its growth strategy.
AoFrio Limited (NZX: AOF) is supporting its core business growth and market
diversification strategy with key additions and changes to its Executive Commercial
Team.
James Rice has been appointed Chief Revenue Officer and will be a member of the
Executive Team. He joins AoFrio from Orion Health, where he held a similar role.
James has more than 25 years’ experience in the software industry, specializing in
sales and business management. His previous roles include Asia Pacific Industry
General Manger at CSC (now DXC), Managing Director at iSoFT and Sales Director
at iSOFT. James brings to AoFrio a wealth of knowledge from running software
businesses for design, development, market entry, sales delivery, customer
adoption, and operational support. Supporting our customers as they increase their
adoption of actionable insights from the AoFrio platform is key to success.
James will lead the development of our sales strategy and its implementation
through our global sales, implementation and support functions.
To support our strategy of growth in new market segments, our current Chief
Customer Officer, David Burden, who has successfully led our global sales,
marketing, implementation, and support teams since 2021, will move to the role of
Chief Business Development Officer - Emerging Markets. AoFrio is well positioned
for entry and growth in these segments and David’s leadership will be key to this
strategy.
AoFrio’s CEO Greg Balla said, “These new roles are critical to AoFrio’s continued
growth; James brings outstanding global sales experience and leadership, and we
can leverage David’s extensive experience in management of business startups in
our emerging markets.”
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- FBU — Fletcher Building: Fletcher Building Executive team announcements2023-12-13
“Fletcher Building Limited, Private Bag 92114, Auckland 1142, 810 Great South Road, Penrose, Auckland 1061, New Zealand Fletcher Building Executive team announcements Auckland, 14 December 2023: Fletcher Building today announced the appointment of Gareth O’Reilly f…”
- FBU — Fletcher Building: Fletcher Building announces Executive appointment2024-02-26
“Fletcher Building Limited, Private Bag 92114, Auckland 1142, 810 Great South Road, Penrose, Auckland 1061, New Zealand Fletcher Building Announces Executive Appointment Auckland, 27 February 2024: Fletcher Building Ltd today announced the appointment of James Peters to…”
- AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS2024-01-08
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 9 January 2024 NEW YEAR LETTER TO INVESTORS AFT poised to accelerate momen…”